It is reported that Baicheng Pharmaceutical was founded on 20 1 1, which is an innovative technology company with research and development as its core. The research scope covers target tracking, compound design and screening, pharmacological and toxicological tests, raw material synthesis, preparation research, quality research, clinical research, drug registration, public testing, MAH and so on. In 20021to1-September, the revenue was 222 million yuan, a year-on-year increase of 77.40%; The net profit was 64,565,438+0.88 million, up 208.88% year-on-year.
Baicheng pharmaceutical shareholders
Before the IPO,
The controlling shareholder and actual controller of Baicheng Pharmaceutical are Shao Chunneng and Lou Jin Fang, with a total shareholding ratio of 47.34%.
. Other shareholders are as follows: Paradise Silicon Valley holds 5.55%, Qinghai Investment holds 4.56%, Phoenix Seal and Xincheng Industry hold 3.7%, Maicheng Pharmaceutical holds 3.5 1%, Wang Weijun holds 3.33%, Zhao Junfei and Yao Hong hold 2.77% and Yi Rui Investment holds 2.22% respectively.
According to the latest announcement, the issue price of Baicheng Pharmaceutical is 79.60 yuan/share, and the subscription dates for offline issuance and online subscription are 202165438+February 9. Some analysts believe that you can actively participate in the purchase of Baicheng Medicine. what do you think?